Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206427 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant GW572016 to Treat Breast Cancer
A Phase 2 study, sponsored by Baylor Breast Care Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00206427: Completed Phase 2 study, sponsored by Baylor Breast Care Center.
NCT00206427 is a Phase 2 study that has completed, run by Baylor Breast Care Center. The registered enrollment target is 49 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206427, a Phase 2 study, has completed, sponsored by Baylor Breast Care Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
We want to learn whether GW572016 is effective in breast cancers that have HER2.
Primary Outcome
Clinical efficacy was assessed by bidimensional tumor measurements of the primary cancer at baseline, and at the end of week 6. Clinical complete response (cCR) was defined as complete disappearance of the primary tumor. Clinical partial response (cPR) was defined as a decrease by at least 50% of the sum of the products of the largest perpendicular diameters. An increase of more than 25% was defined as clinical progressive disease (cPD). Any response that does not meet the definition of cCR, cPR
Interventions
- DRUG lapatinib
- DRUG GW572016
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2004-08 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
What the finished NCT00206427 record still lists
NCT00206427 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 2 interventions - of which lapatinib is the first listed.
NCT00206427 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00206427 about?
NCT00206427 is a clinical study titled "Neoadjuvant GW572016 to Treat Breast Cancer". We want to learn whether GW572016 is effective in breast cancers that have HER2.
What is the current status of trial NCT00206427?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2004-08. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00206427?
The interventions under investigation include: lapatinib (DRUG), GW572016 (DRUG).
Who is sponsoring clinical trial NCT00206427?
This trial is sponsored by Baylor Breast Care Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00206427's enrollment target sits among peer trials
49 1261st of 2000 higher than 736 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia